powered by Surfing Waves

Latest News

Necessity of 2 Doses of the Pfizer and Moderna COVID-19 Vaccines

03 Feb 2021

Two doses of the Pfizer and Moderna COVID-19 vaccines are necessary to confer adequate immunity. The new vaccines for coronavirus disease 2019 (COVID-19) are highly effective, but controversy exists about whether a second dose should be delayed in order to immunize more people. The second dose is necessary and should be given.

Did you have COVID-19? You could be reinfected by new variants

03 Feb 2021

People who already were infected with COVID-19 could face reinfection if the new coronavirus variants become the dominant strains, Dr. Anthony Fauci said Monday.

Coronavirus is in the air — there’s too much focus on surfaces

02 Feb 2021

Catching the coronavirus from surfaces is rare. The World Health Organization and national public-health agencies need to clarify their advice.

Lasting immunity found after recovery from COVID-19

26 Jan 2021

After people recover from infection with a virus, the immune system retains a memory of it. Immune cells and proteins that circulate in the body can recognize and kill the pathogen if it’s encountered again, protecting against disease and reducing illness severity.

Racial and Ethnic Health Disparities Related to COVID-19

22 Jan 2021

One of the most disturbing aspects of the coronavirus disease 2019 (COVID-19) pandemic in the US is the disproportionate harm that it has caused to historically marginalized groups. Black, Hispanic, and Asian people have substantially higher rates of infection, hospitalization, and death compared with White people.


Even Partial COVID-19 Vaccination Protects Nursing Home Residents

17 May 2021

A CDC analysis has shown that a single dose of the Pfizer-BioNTech COVID-19 vaccine protected medically vulnerable nursing home residents as well as it did general adult populations that were evaluated in other efficacy and effectiveness studies.

Delayed Localized Hypersensitivity Reactions to the Moderna COVID-19 Vaccine

12 May 2021

The Moderna COVID-19 vaccine may cause a delayed localized hypersensitivity reaction with a median latency to onset of 7 days after vaccine administration. This pruritic and variably tender reaction has a median duration of 5 days, but may persist for up to 21 days, and may occur again and sooner after the second vaccine dose; no serious adverse events were observed in association with this cutaneous reaction to the Moderna COVID-19 vaccine.

The epidemiological impact of the NHS COVID-19 App

12 May 2021

The COVID-19 pandemic has seen digital contact tracing emerge around the world to help prevent spread of the disease. A mobile phone app records proximity events between app users, and when a user tests positive for COVID-19, their recent contacts can be notified instantly. Theoretical evidence has supported this new public health intervention1-6, but its epidemiological impact has remained uncertain7. Here we investigated the impact of the NHS COVID-19 app for England and Wales, from its launch on 24 September 2020 through to the end of December 2020. It was used regularly by approximately 16.5 million users (28% of the total population), and sent approximately 1.7 million exposure notifications: 4.4 per index case consenting to contact tracing. We estimated that the fraction of app-notified individuals subsequently showing symptoms and testing positive (the secondary attack rate, SAR) was 6.0%, comparable to the SAR for manually traced close contacts. We estimated the number of cases averted by the app using two complementary approaches. Modelling based on the notifications and SAR gave 284,000 (108,000-450,000), and statistical comparison of matched neighbouring local authorities gave 594,000 (317,000-914,000). Roughly one case was averted for each case consenting to notification of their contacts. We estimated that for every percentage point increase in app users, the number of cases can be reduced by 0.8% (modelling) or 2.3% (statistical analysis). These findings provide evidence for continued development and deployment of such apps in populations that are awaiting full protection from vaccines.

Preliminary Findings of mRNA Covid-19 Vaccine Safety in Pregnant Persons

22 Apr 2021

BACKGROUND Many pregnant persons in the United States are receiving messenger RNA (mRNA) coronavirus disease 2019 (Covid-19) vaccines, but data are limited on their safety in pregnancy. CONCLUSIONS Preliminary findings did not show obvious safety signals among pregnant persons who received mRNA Covid-19 vaccines. However, more longitudinal follow-up, including follow-up of large numbers of women vaccinated earlier in pregnancy, is necessary to inform maternal, pregnancy, and infant outcomes.

Association of Race/Ethnicity With Likeliness of COVID-19 Vaccine Uptake Among Health Workers and the General Population in the San Francisco Bay Area

30 Mar 2021

Surveys have demonstrated racial differences in the public’s willingness to receive a COVID-19 vaccine1,2 but have not directly compared vaccine intentions among health workers and the general public.3 We investigated COVID-19 vaccine intentions among racially and ethnically diverse samples of health workers and the general population.

Enroll for Free